In Hour 2 of The Clay Travis and Buck Sexton Show, Buck Sexton is joined by journalist and Substack author Alex Berenson for a deep-dive discussion on the latest developments in public health policy, pharmaceutical industry trends, and higher education accountability. This hour delivers critical insights into the CDC’s recent decision to remove the COVID-19 vaccine from the immunization schedule for healthy children and pregnant women—a move Berenson argues is long overdue but still insufficient. The conversation critiques the FDA and CDC’s cautious approach, highlighting the political and institutional resistance to acknowledging past missteps in pandemic-era health guidance. Berenson also explores the broader implications of vaccine efficacy, particularly for adults under 65, and the lack of rigorous new clinical trials. He emphasizes the need for a complete reevaluation of mRNA vaccine protocols, citing the European model as a more scientifically grounded approach. The discussion touches on the role of public figures like Robert F. Kennedy Jr. and new FDA leadership in pushing for reform, while also addressing the backlash from entrenched public health officials. The hour transitions into a compelling critique of the pharmaceutical industry’s evolution. Berenson outlines how the “golden age” of drug discovery—marked by affordable, effective small-molecule drugs like statins and blood pressure medications—has given way to an era dominated by expensive biologics with limited efficacy. He uses examples like Keytruda and GLP-1 drugs (e.g., Ozempic) to illustrate how Big Pharma now focuses on niche, high-cost treatments for complex conditions like cancer and autoimmune diseases, rather than broad-impact medications. Buck and Berenson also discuss the potential of emerging technologies like CRISPR and AI in drug development. Despite the hype, Berenson remains skeptical, noting that breakthroughs in gene editing and artificial intelligence have yet to deliver transformative results for complex diseases such as schizophrenia or autism. In the final segment, Buck shifts focus to the Trump administration’s push to cut federal funding to Harvard University. He argues that elite institutions like Harvard have become bastions of left-wing ideology and unconstitutional racial discrimination, citing the Supreme Court’s ruling against affirmative action. Buck defends the move as a necessary step to hold universities accountable for their admissions practices and ideological bias, especially in light of recent antisemitism controversies on campus. He draws parallels to NPR and other federally funded institutions, asserting that taxpayer dollars should not support organizations that defy constitutional principles.